Key result
Chronic kidney disease is equivalent to coronary artery disease in terms of mortality risk and acts as a major independent predictor of adverse cardiovascular outcomes in patients with acute coronary syndrome.
Why the study?
Cardiovascular disease is the main cause of death in CKD, yet CKD patients have often been excluded from major ACS trials, leading to improper therapeutic management.
This review highlights the complex pathophysiological connections between CKD and ACS, emphasizing the need for proper control of uremic risk factors and inclusion of CKD patients in clinical trials.
The main causes of death in patients with chronic kidney disease (CKD) are of cardiovascular nature. The interaction between traditional cardiovascular risk factors (CVRF) and non-traditional risk factors (RF) triggers various complex pathophysiological mechanisms that will lead to accelerated atherosclerosis in the context of decreased renal function. In terms of mortality, CKD should be considered equivalent to ischemic coronary artery disease (CAD) and properly monitored. Vascular calcification, endothelial dysfunction, oxidative stress, anemia, and inflammatory syndrome represents the main uremic RF triggered by accumulation of the uremic toxins in CKD subjects. Proteinuria that appears due to kidney function decline may initiate an inflammatory status and alteration of the coagulation-fibrinolysis systems, favorizing acute coronary syndromes (ACS) occurrence. All these factors represent potential targets for future therapy that may improve CKD patient's survival and prevention of CV events. Once installed, the CAD in CKD population is associated with negative outcome and increased mortality rate, that is the reason why discovering the complex pathophysiological connections between the two conditions and a proper control of the uremic RF are crucial and may represent the solutions for influencing the prognostic. Exclusion of CKD subjects from the important trials dealing with ACS and improper use of the therapeutical options because of the declined kidney functioned are issues that need to be surpassed. New ongoing trials with CKD subjects and platelets reactivity studies offers new perspectives for a better clinical approach and the expected results will clarify many aspects.
No takes yet. Share an insight, caveat, or question.
Moisi et al. (2021) conducted a review in Acute Coronary Syndrome in Chronic Kidney Disease. Chronic Kidney Disease vs. Preserved renal function was evaluated. Chronic kidney disease is equivalent to coronary artery disease in terms of mortality risk and acts as a major independent predictor of adverse cardiovascular outcomes in patients with acute coronary syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: